Stock of Spruce Biosciences, Inc. (SPRB) is falling about 5 percent during Wednesday morning trading despite announcement of positive outcomes from two recent Type B meetings with the U.S. FDA regarding its planned biologics license application for tralesinidase alfa enzyme replacement therapy or TA-ERT.
The company's stock is currently trading at $54.79, down 5.93 percent or $3.45, over the previous close of $58.24 on the Nasdaq. It has traded between $7.00 and $2,508.75 in the past one year.
The company anticipates BLA Submission for TA-ERT in the fourth quarter to accommodate FDA's drug product process performance qualification requirement.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.